Equities Analysts Offer Predictions for PTCT FY2026 Earnings

Key Points

• Cantor Fitzgerald has lowered its earnings per share (EPS) estimate for PTC Therapeutics for FY2026 from ($3.22) to ($4.36), while maintaining an "Overweight" rating and a price target of $120.00.
• PTC Therapeutics recently reported a quarterly EPS of $10.04, significantly exceeding expectations of $0.85, although revenue fell 9.6% year-over-year.
• Multiple analysts have adjusted their target prices for PTC Therapeutics, with recommendations ranging from "neutral" to "buy," and an overall consensus price target of $69.38.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2026 earnings per share estimates for shares of PTC Therapeutics in a research note issued on Tuesday, July 29th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceutical company will earn ($4.36) per share for the year, down from their previous estimate of ($3.22). Cantor Fitzgerald currently has a "Overweight" rating and a $120.00 target price on the stock. The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 EPS for the quarter, topping analysts' consensus estimates of $0.85 by $9.19. The company had revenue of $1.18 billion for the quarter, compared to analysts' expectations of $437.16 million. PTC Therapeutics had a negative return on equity of 78.56% and a net margin of 33.56%. PTC Therapeutics's revenue was down 9.6% on a year-over-year basis. During the same quarter last year, the business earned ($1.20) earnings per share.

Other equities analysts have also issued reports about the company. JPMorgan Chase & Co. cut their price objective on PTC Therapeutics from $75.00 to $67.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. UBS Group lifted their price objective on PTC Therapeutics from $71.00 to $80.00 and gave the stock a "buy" rating in a research note on Tuesday. Truist Financial lifted their price objective on PTC Therapeutics from $80.00 to $86.00 and gave the stock a "buy" rating in a research note on Tuesday. Citigroup lifted their target price on PTC Therapeutics from $40.00 to $50.00 and gave the stock a "neutral" rating in a report on Monday. Finally, Barclays lifted their target price on PTC Therapeutics from $42.00 to $46.00 and gave the stock an "equal weight" rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, PTC Therapeutics has an average rating of "Moderate Buy" and an average price target of $69.38.

PTC Therapeutics Stock Up 0.0%

Shares of PTCT stock traded up $0.02 during mid-day trading on Thursday, reaching $52.13. 1,020,621 shares of the stock traded hands, compared to its average volume of 1,123,253. The stock's fifty day simple moving average is $49.08 and its two-hundred day simple moving average is $48.63. PTC Therapeutics has a 1-year low of $29.01 and a 1-year high of $58.38. The company has a market cap of $4.13 billion, a price-to-earnings ratio of 8.01 and a beta of 0.54.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC purchased a new position in shares of PTC Therapeutics during the first quarter valued at approximately $595,000. Allspring Global Investments Holdings LLC purchased a new position in shares of PTC Therapeutics during the first quarter valued at approximately $524,000. Cerity Partners LLC purchased a new position in PTC Therapeutics in the first quarter worth $641,000. Edgestream Partners L.P. purchased a new position in PTC Therapeutics in the first quarter worth $418,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in PTC Therapeutics by 49.2% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 46,894 shares of the biopharmaceutical company's stock worth $2,117,000 after purchasing an additional 15,459 shares during the last quarter.

Insider Activity at PTC Therapeutics

In related news, VP Mark Elliott Boulding sold 883 shares of PTC Therapeutics stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $46.02, for a total transaction of $40,635.66. Following the transaction, the vice president owned 103,901 shares of the company's stock, valued at $4,781,524.02. The trade was a 0.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Pierre Gravier sold 2,516 shares of PTC Therapeutics stock in a transaction that occurred on Tuesday, July 15th. The shares were sold at an average price of $49.46, for a total value of $124,441.36. Following the transaction, the chief financial officer directly owned 71,920 shares in the company, valued at approximately $3,557,163.20. The trade was a 3.38% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,328 shares of company stock valued at $254,158. Corporate insiders own 5.50% of the company's stock.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.